Inflammatory polyarthritis induced by nivolumab treatment in a patient with malignant melanoma: A case report

Authors

  • Osman Cure Recep Tayyip Erdogan University, Faculty of Medicine, Department of Rheumatology, Rize, Türkiye
  • Kadir Ilkkilic Recep Tayyip Erdogan University, Faculty of Medicine, Department of Hematology, Rize, Türkiye
  • Mehmet Sakir Altuner Malatya Education And Research Hospital, Clinic of Rheumatology, Malatya, Türkiye

Keywords:

Melanoma, Nivolumab, Inflammatory polyarthritis

Abstract

Nivolumab is a monoclonal antibody that inhibits the programmed death ligand 1 from binding with PD-1 and restricts T-cell inactivation against cancer cells.

After the introduction of nivolumab, in addition to its known side effects, its relationship with some rheumatic diseases has been reported, but it has not been clearly demonstrated.

Here, we presented a case of inflammatory polyarthritis in a patient treated with nivolumab for malignant melanoma.

This case resulted from the use of PD-1 blocker; It supports that we should be careful about rare side effects besides causing some adverse events due to autoimmune activation in patients.

Downloads

Download data is not yet available.

Downloads

Published

2023-04-28

Issue

Vol. 30 No. 4 (2023): April

Section

Case Reports

License

Copyright (c) 2023 Annals of Medical Research

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

CC Attribution-NonCommercial-NoDerivatives 4.0

How to Cite

1.
Inflammatory polyarthritis induced by nivolumab treatment in a patient with malignant melanoma: A case report. Ann Med Res [Internet]. 2023 Apr. 28 [cited 2025 Feb. 23];30(4):530-2. Available from: http://annalsmedres.org/index.php/aomr/article/view/4411